The H1N1 NR was not written in a way that would entice too many to buy into the story. Knowing the Company and the way they operate, they are more conservative and not all about promotion. Furthermore, the testing they made was done on a new strain, so you do not want to over emphasize what was done, especially that we are talking about mice results.

Given the above, I would not be surprised to see a new 52 high very soon, as there are now many more investors and brokers watching this story closely.

For those that want to see a very close example of how lucrative MDG is have a look at HEB. They passed phase one and their MCAP went 5X due to the results.

This story is just unfolding and many people will start chasing the very limited freely trading shares on any significant news.

MMN